SCHEMBL6820577

SCHEMBL6820577

FC(F)(F)CNc1nc(Cl)nc2c1ncn2C1CCCC1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CTSL P07711 4/20 0.49
CDK1 P06493 3/20 0.49
YTHDC1 Q96MU7 1/20 0.47
ADORA3 P0DMS8 8/20 0.46
ADORA1 P30542 7/20 0.46
ADORA2A P29274 4/20 0.46
ADORA2B P29275 2/20 0.46
CCNB2 O95067 1/20 0.45
CCNE2 O96020 1/20 0.45
CDK4 P11802 1/20 0.45
CCNB1 P14635 1/20 0.45
CCND1 P24385 1/20 0.45
CCNE1 P24864 1/20 0.45
CDK2 P24941 1/20 0.45
CCNB3 Q8WWL7 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
FLT3 P36888 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6821015 0.88 YTHDC1 (0.46) CTSLCDK1YTHDC1ADORA3ADORA1
SCHEMBL6818080 0.84 ADORA3 (0.61) CTSLCDK1YTHDC1ADORA3ADORA1
SCHEMBL6821032 0.83 ADORA3 (0.64) CTSLCDK1YTHDC1ADORA3ADORA1
SCHEMBL5193703 0.82 ADORA3 (0.53) CTSLCDK1YTHDC1ADORA3ADORA1
SCHEMBL6817815 0.82 ADORA3 (0.60) CTSLCDK1YTHDC1ADORA3ADORA1
SCHEMBL6817775 0.82 CTSL (0.59) CTSLCDK1YTHDC1ADORA3ADORA1
SCHEMBL5196313 0.81 CTSL (0.44) CTSLCDK1YTHDC1ADORA3ADORA1
SCHEMBL6944712 0.81 CDK1 (0.57) CTSLCDK1ADORA3ADORA1CCNB2
SCHEMBL6817730 0.80 CTSL (0.54) CTSLCDK1ADORA3ADORA1ADORA2A
SCHEMBL6820593 0.80 CTSL (0.66) CTSLCDK1YTHDC1ADORA3ADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1056745-B1 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES AVENTIS PHARMA INC (US) 2004-06-16 EP disclosed
US-6413974-B1 INHIBITORS OF CYCLIN DEPENDENT KINASES, PARTICULARLY CDK-2; PREVENTING APOPTOSIS IN NEURONAL CELLS; ANTINEOPLASTIC AGENTS; NEURONAL INJURY AND DEGENERATION; CEREBROVASCULAR DISEASE AVENTIS PHARMACEUTICALS INC. 2002-07-02 US disclosed
EP-1056745-A2 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES Aventis Pharmaceuticals Inc. (US) 2000-12-06 EP disclosed
WO-1999043676-A2 6,9-DISUBSTITUTED 2-[TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES AVENTIS PHARMACEUTICALS INC. (US) 1999-09-02 WO disclosed